前列腺癌根治术后辅助放疗与早期挽救性放疗的比较
该多中心倾向评分匹配队列研究纳入1566例根治术后具不良病理特征的前列腺癌患者,比较辅助放疗(ART)与早期挽救性放疗(ESRT)。匹配后ART组12年无生化失败率69%、无远处转移率95%、总生存率91%,均优于ESRT组的43%、85%、79%。
要点
- ART较ESRT显著提高12年无生化失败率(69% vs 43%)。
- ART较ESRT改善无远处转移率(95% vs 85%)和总生存率(91% vs 79%)。
- 多因素分析中ART、较低Gleason评分和T分期、淋巴结照射及术后ADT为有利预后因素。
核心结论
- 对于具不良病理特征的前列腺癌患者,与ESRT相比,ART与更低的生化复发、远处转移和死亡风险相关,尚待前瞻性验证。
研究设计与样本
- 多中心倾向评分匹配队列研究,纳入1987年1月1日至2013年12月31日在美国10家学术医学中心接受术后ART或ESRT的1566例连续患者。
- 采用1:1倾向评分匹配校正治疗选择相关协变量,数据分析时间为2016年10月1日至2017年10月21日。
主要发现
- 1195例PSA 0.1-0.5 ng/mL患者接受ESRT,371例PSA低于0.1 ng/mL患者接受ART,中位年龄60(IQR 55-65)岁。
- ART较ESRT的12年无生化失败率 actuarial 为69%(95%CI 60%-76%)vs 43%(95%CI 35%-51%),效应量26%。
- ART较ESRT的12年无远处转移率为95%(95%CI 90%-97%)vs 85%(95%CI 76%-90%),效应量10%。
- ART较ESRT的12年总生存率为91%(95%CI 84%-95%)vs 79%(95%CI 69%-86%),效应量12%。
关键数值与推荐
- 多因素分析中,ART、较低Gleason评分和T分期、淋巴结照射及术后雄激素剥夺治疗为生化失败的有利预后因素。
- 敏感性分析显示,除非ART组超过56%患者仅通过手术治愈,否则ART与生化失败风险降低的关联仍显著。
- 该56%阈值高于当代动态列线图估算的根治性前列腺切除术后12年无生化失败率33%-52%。
临床怎么用
- 对于根治术后具pT3和/或切缘阳性等不良病理特征的前列腺癌患者,可考虑优先推荐辅助放疗而非监测后早期挽救放疗。
- 决策时应结合Gleason评分、T分期、淋巴结照射及术后雄激素剥夺治疗等预后因素综合评估。
局限性
- 研究为回顾性队列设计,结果需前瞻性验证。
- ART组与ESRT组基于PSA水平分组,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate cancer with adverse pathological features (ie, pT3 and/or positive margins) after prostatectomy may be managed with adjuvant radiotherapy (ART) or surveillance followed by early-salvage radiotherapy (ESRT) for biochemical recurrence. The optimal timing of postoperative radiotherapy is unclear. OBJECTIVE: To compare the clinical outcomes of postoperative ART and ESRT administered to patients with prostate cancer with adverse pathological features. DESIGN, SETTING, AND PARTICIPANTS: This multi-institutional, propensity score-matched cohort study involved 1566 consecutive patients who underwent postprostatectomy ART or ESRT at 10 US academic medical centers between January 1, 1987, and December 31, 2013. Propensity score 1-to-1 matching was used to account for covariates potentially associated with treatment selection. Data were collected from January 1 to September 30, 2016. Data analysis was conducted from October 1, 2016, to October 21, 2017. MAIN OUTCOMES AND MEASURES: Freedom from postirradiation biochemical failure, freedom from distant metastases, and overall survival. All outcomes were measured from date of surgery to address lead-time bias. RESULTS: Of 1566 patients, 1195 with prostate-specific antigen levels of 0.1 to 0.5 ng/mL received ESRT and 371 patients with prostate-specific antigen levels lower than 0.1 ng/mL received ART. The median age (interquartile range) was 60 (55-65) years. After propensity score matching, the median (interquartile range) follow-up after surgery was similar between the ESRT and ART groups (73.3 [44.9-106.6] months vs 65.8 [40-107] months; P = .22). Adjuvant RT, compared with ESRT, was associated with higher freedom from biochemical failure (12-year actuarial rates: 69% [95% CI, 60%-76%] vs 43% [95% CI, 35%-51%]; effect size, 26%), freedom from distant metastases (95% [95% CI, 90%-97%] vs 85% [95% CI, 76%-90%]; effect size, 10%), and overall survival (91% [95% CI, 84%-95%] vs 79% [95% CI, 69%-86%]; effect size, 12%). Adjuvant RT, lower Gleason score and T stage, nodal irradiation, and postoperative androgen deprivation therapy were favorable prognostic features on multivariate analysis for biochemical failure. Sensitivity analysis demonstrated that the decreased risk of biochemical failure associated with ART remained significant unless more than 56% of patients in the ART group were cured by surgery alone. This threshold is greater than the estimated 12-year freedom from biochemical failure rate of 33% to 52% after radical prostatectomy alone, as determined by a contemporary dynamic nomogram. CONCLUSIONS AND RELEVANCE: Adjuvant RT, compared with ESRT, was associated with reduced biochemical recurrence, distant metastases, and death for high-risk patients, pending prospective validation. These findings suggest that a greater proportion of patients with prostate cancer who have adverse pathological features may benefit from postprostatectomy ART rather than surveillance followed by ESRT.
引用
- Hwang WL, Tendulkar RD, Niemierko A, et al. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018. PMID: 29372236. doi:10.1001/jamaoncol.2017.5230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。